Precision Biotechnology International is a company primarily originating from Taiwan's R&D and clinical application of immune cell therapies such as NK/NKT, DC, and hMSC (hereinafter referred to as "Taiwan Precision"). It is a startup company established on December 6, 2017, and has been officially certified as a biotechnology and new drug company by the Ministry of Economic Affairs of Taiwan. Currently, two clinical trials (autologous immune cell preparation PB101 and allogeneic immune cell preparation PB103) are being conducted in Taiwan. A cell laboratory meeting GMP specifications is being utilized to manufacture immune cell products to supply clinical patients at Kaohsiung Medical University Chung-Ho Memorial Hospital, Tungs' Taichung MetroHarbor Hospital, Kuang Tien General Hospital, and Taipei Zhongshan Hospital, which are available for clinical use and charging in accordance with the Regulations Governing the Application of Specific Medical Technology.

After three long years of continuous discussions, due diligence, and site visits with partners of the Global Resources Group, a combination of science and business was achieved. Under the effective integration of both parties' advantages in capital, technology, and capabilities, Precision Biotechnology International Co., Ltd. was co-founded. In July 2021, it passed the admission review of the Hong Kong Science Park and will build the first Advanced Therapy Medicinal Product (ATMP) cell preparation manufacturing facility in the Asia-Pacific region that complies with European PIC/S GMP requirements in Hong Kong and the Greater Bay Area. The preparation of the PB103 allogeneic NK cell product at the Hangzhou, China Precision Proto-Cell Factory has been applied for and is awaiting approval for a large-scale, multi-center Phase I/II clinical trial in China.

Precision Bio Int'l possesses a series of its own core technologies, patents, and know-how in the fields of NK cells and gene editing, and has established a complete genetic engineering platform for NK/NKT cells. In addition to completing proof-of-concept, it is currently being used clinically to treat patients. The R&D pipeline includes multiple global first-in-class universal cell therapy products, with indications covering various solid tumors such as lung cancer and liver cancer, as well as unmet medical needs in hematological malignancies. It is expected that through innovative and outstanding advanced thinking, R&D, clinical application technology, and management, the Precision Biotechnology Group will be built to achieve the vision of "promoting organizational development and becoming a biotechnology company of outstanding reputation," making the Precision Group a leading brand in immune cell cancer therapy, personalized medicine, and immunotherapy application platforms.